Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30554494 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTHTTRAB9AL3MBTL1 | |
| SCHEMBL25338029 | 0.85 | ALDH1A1 (0.59) | ALDH1A1MAPTHTTRAB9AL3MBTL1 | |
| SCHEMBL25338025 | 0.85 | ALDH1A1 (0.59) | ALDH1A1MAPTHTTRAB9AL3MBTL1 | |
| SCHEMBL4656705 | 0.83 | MAPT (0.56) | ALDH1A1MAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL4656702 | 0.83 | MAPT (0.56) | ALDH1A1MAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL16442406 | 0.83 | MAPT (0.56) | ALDH1A1MAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL1403472 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPTHTTL3MBTL1SMN1; SMN2 | |
| SCHEMBL30203403 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPTHTTL3MBTL1SMN1; SMN2 | |
| SCHEMBL29206929 | 0.81 | L3MBTL1 (0.62) | ALDH1A1MAPTHTTRAB9AL3MBTL1 | |
| SCHEMBL30407930 | 0.81 | L3MBTL1 (0.62) | ALDH1A1MAPTHTTRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, ARNT, NR1H2 | ALDH1A1 602/4885MAPT 1282/4885HTT 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.